DOCSLIB.ORG

OLYMPICS -T.P.Sreenivasan IFS (Retd.) Geographical Indications Athens to Tokyo -Dr

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
OLYMPICS -T.P.Sreenivasan IFS (Retd.) Geographical Indications Athens to Tokyo -Dr AUGUST 2021 | Vol 16 | Issue 09 | Trivandrum, India Authenticity, Brevity and Clarity in Knowledge Dissemination Issue 188 Crossing the Rubicon OLYMPICS -T.P.Sreenivasan IFS (Retd.) Geographical Indications Athens to Tokyo -Dr. Raju Narayana Swamy IAS 1 India ` 50 | European Countries 5 | Singapore S$ 10 | UAE Dh 20 | USA $ 6 Dear readers, Editor’s Another edition of Executive Knowledge Lines is now with you. We at EKL always DESK endeavour to make each issue look different in its content diversity. In selection of content, we always earnestly strive to adopt a multi disciplinary approach. How far we succeed in doing that is a matter to be judged by our esteemed readers. Human life still continues to be on a different plane. Though the grip of the pandemic on mankind has been loosening with the passage of time, the threat of a third wave looms large in many parts of the world as cautioned by experts. When certain calamities befall upon the people, the onus of combating them lies as much on the State as on the citizens to the extent both can do so. Government of India has been taking a host of measures to ensure that the citizens are equipped well to face the challenge and threat posed by the growing pandemic. The citizens are being empowered with the right information and precautions as per the Health Ministry’s advisories and best efforts are on to get the entire the population vaccinated. The success of the government’s efforts depends largely on the extent of vigil and compliance on the part of the people. A third wave of the pandemic anticipated to cause an extremely precarious situation, any effort to prevent it would not be too much. This is a responsibility cast on every citizen. It is heartening that this awareness has been gaining grounds. We earnestly hope our readers would find the articles and features in this edition interesting and informative and the issue T.P.Sreenivasan IFS (Retd.) would bring them as much joy as it brings to EKL team. Managing Editor [email protected] Happy reading. www.eklines.com AUGUST 2021 3 Authenticity, Brevity and Clarity in Knowledge Dissemination AUGUST 2021 | Volume 16 | Issue 09 | `50 | Annual Subscription `600 Managing Editor T P Sreenivasan IFS (Retd.) Editor Siji Nair* Executive Editor N Vijayagopalan Executive Director Hari Shanker Advertising & Subscriptions Jayaprakash R P EDITORIAL ADVISORY BOARD Dr. C.V. Ananda Bose IAS (Retd.) James K. Joseph (IA & AS Retd.) Dr. James George Email: [email protected] Padma Shri Prof. Dr. P. Pushpangadan Web: www.eklines.com e-magazine: https://issuu.com/metromart Padma Shri G. Shankar Air Vice Marshal R. Somnath VSM (Retd.) Editorial & Marketing Office MERA 44, Eanthivila lane, G. Rajamohan Murinjapalam, Medical College P.O Dr. C.G. Sukumaran Nair Trivandrum 695 011, Kerala, India Prof. Harimohan Bhattathiri Contact: Dr. K.C. Chandrasekharan Nair Manager ( Knowledge Operations) Tel: 0471 4015593 Mob: 91 9995139933/ 9947733339 Founder: N T Nair Owned, Edited, Printed and Published by Siji Nair, R M Nivas, TMRA F 6 Pangappara (PO) Thiruvananthapuram Pin 695 581. Printed at Akshara Offset TC 25/3230(1), Vanchiyoor, Thiruvananthapuram 695 035. Editor- Siji Nair RNI No. KERENG/2005/16316 Executive Knowledge Lines is a Monthly Journal Published from Trivandrum. Views and Opinions expressed in the Journal are not necessarily those of the Publishers. Executive Knowledge Lines reserves the right to use the information Published here in any manner whatsoever, while every effort has been made to ensure the accuracy of the information published in this edition, neither the publisher nor any of its employees accept any responsibilities for any errors or omissions. *Responsible for selection of news under the PRB Act 4 AUGUST 2021 Executive Knowledge Lines CONTENTS Olympics- Athens to Tokyo 06 AUGUST 2021 | Volume 16 | Issue 09 | `50 | Annual Subscription `600 42 Blood is Meant to Circulate; Pass It Around 45 Laugh It Away India registered its 12 Research and Development best-ever tally of seven 46 efforts in Ethnobotany, medals at the Olympics Ethnomedicine and Ethno- pharmacology Geographical Indications: 16 54 News Reel Test Your GK 27 58 Reflection Crossing the Rubicon 28 Dear Readers COVID-19: An Update On 32 EKL welcomes feedback/opinion/suggestions from Immunity, Vaccine Safety esteemed readers. And Efficacy & As a part of our policy of encouraging promising young writers, EKL solicits contributions from Breakthrough readers. The article can be on science and Infection technology/environment/life style/economy/health/ history/economics or other matters of general interest. The length of the article may be limited to not more than 1500 words. One article selected by Corporate Musings 41 our Editorial Team will be published in each issue. Please mail them to [email protected] www.eklines.com AUGUST 2021 5 Olympics Olympics Athens to Tokyo Abhijit Sankar he Post-Covid world, in something extravagant sitting mostly in quarantine, is in the comfort of their homes. now eagerly watching This Olympics, peculiar for its the Tokyo Olympics. closed nature- devoid of an THumankind has been firefighting audience, devoid of cheers, and its worst crisis by narrowing devoid of protests will forever life to a microscopic world of remain in the history of world isolation. Tokyo Olympics comes sports as the first-ever “Closed with messages of hope, survival, Olympics”. The Olympics in the motivation, and solace to an wake of the pandemic is not a already devastated world. People new experience to the world. around the globe can now indulge This had happened before in 6 AUGUST 2021 Executive Knowledge Lines as superhuman and even questioning science through their performance. We have witnessed people turning their struggles into milestones and gaining fame for their country. We have even seen people becoming synonymous with their lands and vice versa. We have found people performing their best and even perishing in the ground. The Olympics is life and a dream for many. They lead a life of toil to reach their dream, to become a better version of themselves, and to evolve “ faster, stronger and higher. Every Olympics is the story of the athletes who put their lives on hold for four years, and the Olympics will be remembered in the name of those whose story became the history of the 1920 at Antwerp when the moment. It can be a moment Olympics was held following the of victory, a moment of loss, or Spanish Flu. History repeats after even a moment of resistance. a century, and indeed this year, the Olympics might have started History of Olympics with a single common prayer The history of the Olympics from every sports enthusiast that begins from 776 BC, in this shouldn’t repeat in any far or Olympia of Greece. Olympics near future. was fundamentally a religious The beauty of the Olympics lies festival, featuring sporting in its uncertainty. It has often events alongside ritual sacrifices been a mixture of victory and fall, honoring Greek Gods Zeus and pride and shame, survival and Pelops. It also featured theatre hope. The merit of the Olympics performances and music. The is unfathomable as it surpasses celebrations were held every four the podium finishes and medals. years at the sanctuary of Zeus, The history of the Olympics featuring competitions between is indisputably the history of the different city-states of humankind. Over the years, the Greece. The ancient Olympics is world has seen people evolving shrouded in myths and religion, www.eklines.com AUGUST 2021 7 being the Greeks’ way of saluting with disabilities and youth their gods. The four years were Olympics were also started by called Olympiads and were used the IOC. as a measurement by ancient Greeks. But when Romans gained Olympics and Politics power and influence in Greece, Olympics is an arena where Olympics lost its glory. In 393 athletes representing various AD, Roman emperor Theodosius countries compete, and hence banned Olympics. there are no individuals but countries. And thus, Olympics in Modern games different points of history have The revival of the Olympic become a center of dispute Games took place in 1896 and and controversies. This makes it has been staged every fourth Olympics a game of countries year since World War I and and whatever befalls people World War II (1916, 1940, 1944). befalls Olympics, such as power, Pierre de Coubertin (1863–1937), politics, or protest. The Olympics a young French nobleman, is of 1936 in Germany became a known as ‘the father of modern stage for protest against the Nazi Olympics’. His determination regime during the period. The and organizational skills have Munich Olympics,1972 witnessed helped the Olympics achieve its 11 participants from Israel by current stature. He founded the a Palestinian terrorist group at International Olympic Council the Olympic Village. The 1976 (IOC) and organized the Olympic Montreal Olympics is noted for Congress in 1894, which acted as the resistance and messages by a catalyst for the rebirth of the African athletes against apartheid Olympics at the Panathinaikos in South Africa Stadium in Athens in 1896. Two Tokyo Olympics 2020, too, has hundred forty-one athletes not been immune to protests. from 14 different countries People of Japan were skeptical participated in the 1896 games, about the economic crisis that and the USA won 9 events out the Olympics would bring to of 12. their country, whose economy The initial years of the modern is already struggling due to Olympics following the 1896 Covid-19. The presence of the Olympics lacked popular Refugee team right from the Rio support. It remained in a Olympics is another instance that period of stagnation until the makes the Olympics truly a game Paris Olympics, 1924.
Load more

Recommended publications
  • What Do We Know About India's Covaxin Vaccine?
    FEATURE Tamil Nadu, India COVID-19 VACCINES [email protected] BMJ: first published as 10.1136/bmj.n997 on 20 April 2021. Downloaded from Cite this as: BMJ 2021;373:n997 http://dx.doi.org/10.1136/bmj.n997 What do we know about India’s Covaxin vaccine? Published: 20 April 2021 India has rapidly approved and rolled out Covaxin, its own covid-19 vaccine. Kamala Thiagarajan examines what we know so far. Kamala Thiagarajan freelance journalist Who developed Covaxin? cheapest purchased by any country in the world at 206 rupees per shot for the 5.5 million doses the Covaxin was developed by Indian pharmaceutical government currently has on order. The government company Bharat Biotech in collaboration with the has capped the price of the vaccine sold in the private Indian Council of Medical Research, a government market, with private hospitals able to charge up to funded biomedical research institute, and its 250 rupees.13 subsidiary the National Institute of Virology. Covaxin does not require storage at sub-zero Bharat Biotech has brought to market 16 original temperatures, which would be hard to maintain in vaccines, including for rotavirus, hepatitis B, Zika India’s climate and with the frequent power cuts in virus, and chikungunya.1 The company reportedly rural areas. Covaxin is available in multi-dose vials spent $60-$70m (£43-£50m; €50-€58m) developing and is stable at the 2-8°C that ordinary refrigeration Covaxin.2 can achieve. How does Covaxin work? Bharat Biotech says it has a stockpile of 20 million The vaccine is similar to CoronaVac (the Chinese doses of Covaxin for India and is in the process of vaccine developed by Sinovac)3 in that it uses a manufacturing 700 million doses at its four facilities complete infective SARS-CoV-2 viral particle in two cities by the end of the year.
    [Show full text]
  • 0 January to July 2021
    0 www.journalsofindia.com January to July 2021 SCIENCE & TECH ............................................................................................................................................................... 6 1. REUSABLE LAUNCH VEHICLE TECHNOLOGY DEMONSTRATION PROGRAMME(RLV-TD) ................................................. 6 2. GAGANYAAN MISSION ..................................................................................................................................................... 6 3. MARS ORBITER MISSION (MOM) ..................................................................................................................................... 6 4. CHANDRAYAAN MISSION................................................................................................................................................. 7 5. SOLAR MISSION ............................................................................................................................................................... 8 6. ARTEMIS ACCORD ............................................................................................................................................................ 9 7. NATIONAL MISSION ON INTERDISCIPLINARY CYBER-PHYSICAL SYSTEM (NMICPS) ....................................................... 10 8. SMART ANTI-AIRFIELD WEAPON (SAAW) ...................................................................................................................... 10 9. AQUAPONICS ................................................................................................................................................................
    [Show full text]
  • Bcpct]Ttsbc^Prc U^A Dq[XRV^^S
    6 < %()(=#%% 53%7==,>3='$()6(=#%% (#-'>3='$()6(=#%% $'()"*$+&,- %( !"# $$%& 2(*3-% (566)(37)% 3 0 4 $5 3 $1 2 0 .8 9 8 ++0 0 .:; . !" . / 01 $ %'( $) '# *' it for the last eight to nine notable achievements to its months, “where is the UN in name in the 75 years of its aking a strong case for a this joint fight. Where is the experience, including the pre- Msignificant role for India effective response.” vention of a third world war, in the United Nations, Prime Focussing on a more “we can’t deny terrorist attacks 0 Minister Narendra Modi on prominent role for India in the shook the world”. Saturday stressed the need for UN and fight against corona, “We have successfully ne of the oldest partners changes in the international the Prime Minister avoided avoided a third world war but Oof the BJP — the body and questioned its posi- making any reference to ongo- we cannot deny many wars Shiromani Akali Dal — which tion in fighting the coron- ing tension at the Line of happened, many civil wars has been with it through thick avirus pandemic. Actual Control (LAC) and happened. Terrorist attack and thin for decades, finally He also assured the global frosty ties with Pakistan in his shook the world. Blood was quit the National Democratic Q community that India will pro- 20-minute speech. He also did spilled. Those were killed were Alliance (NDA) on Saturday, vide corona vaccine to the not respond to Pakistan Prime like you and me. Children left signaling a complete political world as it is the world’s biggest Minister Imran Khan’s remarks the world prematurely,” he said.
    [Show full text]
  • COVID-19 Vaccines Update Supplement Week Of: 5Th April, 2021
    CARPHA UPDATE FOR Incident Manager / SITUATION REPORT COVID-19 Vaccines Update Supplement Week of: 5th April, 2021 I. Overview of Development and Regulatory Approvals: • 85 candidate vaccines are in clinical development: 16 in Phase 3 trials, and 4 in Phase 4 trials – see Figure in CARPHA COVID-19 Vaccine Regulatory Tracker (Phases tab). • 13 vaccines have received regulatory approvals in various countries, and 16 vaccines are at various stages of engagement with WHO for emergency use listing (EUL). • 4 vaccines have been approved by WHO for Emergency Use Listing: Pfizer-BioNTech’s vaccine: COMIRNATY®, AstraZeneca-SK Bio, AstraZeneca-SII (Covishield), and Janssen-Cilag. • 4 additional vaccines are expected to be approved by WHO in April – Tables 1 and 3. • There are 3 additional vaccines being considered by WHO but these are at the stage of submitting expressions of interest: Bharat Biotech, Clover Biopharmaceuticals-GSK + Dynavax, and BioCubaFarma (Cuba). • The WHO Strategic Advisory Group of Experts on Immunization (SAGE) interim recommendations and background documents are available for vaccines by: Moderna, Pfizer-BioNTech, AstraZeneca-Oxford and Janssen-Cilag at SAGE Interim Guidance. The recommendations provide guidance on the use the vaccines, including use in various groups. • Reports of rare clotting events among vaccinees continue to be assessed by various regulators. The EU's European Medicines Agency (EMA) has stated that there was no evidence to support decisions by regulators to restrict the use of Oxford-AstraZeneca vaccines in some age groups. The WHO maintains that the benefit-risk balance of the vaccine remains favorable. • CARPHA has shared its COVID-19 vaccine regulatory tracker with Member States for viewing as updates are made.
    [Show full text]
  • V.3 1/25/2021 COVID-19 Vaccine FAQ Sheet
    COVID-19 Vaccine FAQ Sheet (updated 1/25/2021) The AST has received queries from transplant professionals and the community regarding the COVID-19 vaccine. The following FAQ was developed to relay information on the current state of knowledge. This document is subject to change and will be updated frequently as new information or data becomes available. What kinds of vaccines are available or under development to prevent COVID-19? There are currently several vaccine candidates in use or under development. In the United States, the Government is supporting six separate vaccine candidates. Several other vaccines are also undergoing development outside of the United States government sponsorship and further information can be found here: • NYTimes Coronavirus Vaccine Tracker: https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine- tracker.html • Washington Post Vaccine Tracker: https://www.washingtonpost.com/graphics/2020/health/covid-vaccine-update- coronavirus/ The types of vaccines are as follows (January 25, 2021) 1: Table 1: Vaccines Under Development Vaccine Type Compound Name Clinical Trial Notes [Sponsor] Phase mRNA mRNA-1273 Phase 3 Emergency use in [Moderna] U.S., E.U., other countries Approved in Canada BNT162b2 [Pfizer] Phase 2/3 Emergency use in U.S., E.U., other countries Also approved in Canada and other countries Replication- AZD1222 Phase 2/3 Emergency use in defective [AstraZeneca] Britain, India, other adenoviral vector countries (not U.S.) Ad26.COV2.S Phase 3 [Janssen] v.3 1/25/2021 Recombinant- NVX-CoV2373 Phase 3 subunit-adjuvanted [Novavax] protein Recombinant SARS- Phase 1/2 CoV-2 Protein Antigen + AS03 Adjuvant [Sanofi Pasteur/GSK] Inactivated CoVaxin [Bharat Phase 3 Emergency Use in coronavirus Biotech] India BBIBP-CorV Phase 3 Approved China, [Sinopharm] Bahrain, UAE; Emergency use elsewhere (not U.S.) Both of the mRNA SARS-CoV-2 vaccines (Moderna, Pfizer) have been approved by Emergency Use Authorization by the U.S.
    [Show full text]
  • COVID-19 Vaccination Programme: Information for Healthcare Practitioners
    COVID-19 vaccination programme Information for healthcare practitioners Republished 6 August 2021 Version 3.10 1 COVID-19 vaccination programme: Information for healthcare practitioners Document information This document was originally published provisionally, ahead of authorisation of any COVID-19 vaccine in the UK, to provide information to those involved in the COVID-19 national vaccination programme before it began in December 2020. Following authorisation for temporary supply by the UK Department of Health and Social Care and the Medicines and Healthcare products Regulatory Agency being given to the COVID-19 Vaccine Pfizer BioNTech on 2 December 2020, the COVID-19 Vaccine AstraZeneca on 30 December 2020 and the COVID-19 Vaccine Moderna on 8 January 2021, this document has been updated to provide specific information about the storage and preparation of these vaccines. Information about any other COVID-19 vaccines which are given regulatory approval will be added when this occurs. The information in this document was correct at time of publication. As COVID-19 is an evolving disease, much is still being learned about both the disease and the vaccines which have been developed to prevent it. For this reason, some information may change. Updates will be made to this document as new information becomes available. Please use the online version to ensure you are accessing the latest version. 2 COVID-19 vaccination programme: Information for healthcare practitioners Document revision information Version Details Date number 1.0 Document created 27 November 2020 2.0 Vaccine specific information about the COVID-19 mRNA 4 Vaccine BNT162b2 (Pfizer BioNTech) added December 2020 2.1 1.
    [Show full text]
  • Bharat Biotech Inks Licensing Deal with Washington University School of Medicine in St
    Bharat Biotech Inks Licensing Deal with Washington University School of Medicine in St. Louis to advance COVID-19 Intranasal Vaccine Technology Hyderabad, India, 23 September 2020: Vaccine Innovator, Bharat Biotech announces today, a licensing agreement with Washington University School of Medicine in St. Louis for a novel chimp- adenovirus, single dose intranasal vaccine for COVID-19. Bharat Biotech owns the rights to distribute the vaccine in all markets except USA, Japan and Europe. While the Phase I trials will take place in Saint Louis University’s Vaccine & Treatment Evaluation Unit, Bharat Biotech, upon obtaining the required regulatory approval, will pursue further stages of clinical trials in India and undertake large scale manufacture of the vaccine at its GMP facility located in Genome Valley, Hyderabad. We are proud to collaborate on this innovative vaccine. We envision that we will scale this vaccine to 1 billion doses, translating to 1 billion individuals vaccinated receiving a single-dose regimen. An intranasal vaccine will not only be simple to administer but reduce the use of medical consumables such as needles, syringes, etc., significantly impacting the overall cost of a vaccination drive. Our experience in viral vaccines, manufacturing capabilities, and distribution continue to be our strong suit in ensuring safe, efficacious, and affordable vaccines. It is prudent for Bharat to be involved in diverse but tenable projects to provide a much-needed vaccine against COVID-19 reaches all citizens of the world.” Dr. Krishna Ella, Chairman and Managing Director of Bharat Biotech, stated. This intranasal vaccine candidate has shown unprecedented levels of protection in mice studies; the technology and data having been recently published in the prestigious scientific journal Cell and in an editorial in Nature.
    [Show full text]
  • Editorial 10.5005/Ijmb-24-3-Iv
    Editorial 10.5005/ijmb-24-3-iv COVID-19 Vaccines: Lets Go for It SARS CoV-2, also christened as COVID-19 is an acute respiratory illness caused by a novel coronavirus which originated from Wuhan China in 2019 and within a short span affected virtually each and every country around the globe, throwing healthcare preparedness and economy out of gear. The world was faced with a pandemic leading to overcrowded hospitals and overflowing mortuaries. Lockdowns imposed in countries jeopardized routine life never to normalize again. India has been among the top three countries with the maximum number of afflicted people. Thankfully , our statistics with respect to mortality is better as compared to the western world. The last year 2020 was completely COVIDISED if we may say so. The world economy is in doldrums and the health infrastructure is overstretched and fatigued. Everytime we feel that the disease is under control, the virus cleverly mutates to become more infective and develops increased ability to escape the immune surveillance. Efforts to develop a vaccine against this scourge were initiated at a war footing across the globe. A number of vaccines were approved for emergency use since the scientific committee didn’t have the time to wait further. In India, two vaccines- Covaxin and Covishield have been approved by the Government of India for mass vaccination. The mammoth program was initiated with first preference for the healthcare workers and frontline warriors. In the next phases, elderly population followed by the rest of the population in a phased manner was planned. It is really incredible and praiseworthy about the immaculate planning and implementation of the initiative in our country where the diversity is both a boon as well as bane.
    [Show full text]
  • COVID-19 VACCINE FREQUENTLY ASKED QUESTIONS What You Need to Know
    THE REPUBLIC OF UGANDA MINISTRYMINISTRY OF HEALTH COVID-19 VACCINE FREQUENTLY ASKED QUESTIONS What You Need to Know Introduction This document contains the frequently asked questions and answers to provide you with information on the COVID-19 vaccines and why it is important for you to get vaccinated, or encourage those around you to get vaccinated as long as they are eligible. General information about COVID-19 and COVID-19 Vaccine 1. What is the Coronavirus Disease of 2019 (COVID-19) and how does it spread? COVID-19 is an infectious respiratory disease caused by the coronavirus, SARS-CoV-2. The World Health Organisation (WHO) first learned of this new virus from cases in Wuhan city in China on 31st December 2019. The virus can spread from an infected person’s mouth or nose in small liquid particles (droplets) when they cough, sneeze, talk, sing or breathe heavily. The main way the virus spreads is when people are in direct or close contact (less than 1 meter) with an infected person. 1 2. What are the signs and symptoms of COVID-19 infection? • The most common symptoms of COVID-19 are fever, dry cough, and fatigue. • Other symptoms that are less common include loss of taste or smell, nasal congestion, conjunctivitis (red eyes), sore throat, headache, muscle or joint pain, skin rash, nausea or vomiting, diarrhea, chills or dizziness. Symptoms are usually mild. • Some people may get infected and progress to severe disease. Symptoms of severe COVID-19 disease include shortness of breath, loss of appetite, confusion, persistent pain or pressure in the chest, and high temperature (above 38°C).
    [Show full text]
  • Asia COVID-19 & Vaccine Tracker
    9 July 2021 Free to View Asia COVID-19 & Vaccine Tracker Economics - Asia Tougher restrictions As COVID-19 cases continue to surge across Asia, more Yun Liu authorities have re-imposed restrictions or even lockdowns Economist The Hongkong and Shanghai Banking Corporation Limited But this has increased the urgency to ramp up vaccine Frederic Neumann procurement and roll-out in the region Co-Head of Asian Economics Research The Hongkong and Shanghai Banking Corporation Limited Some economies have started pilot programmes to revive tourism, but a full re-opening may take a long time Maitreyi Das Associate Bangalore Déjà vu No end in sight just yet. The Delta variant is causing daily new COVID-19 cases to surge to new record highs across Asia, prompting more governments to re-impose tougher restrictions. This is particularly evident in ASEAN, where cases in Indonesia and Vietnam have been rising sharply. The former has extended its tightening measures throughout the country until 20 July, while the latter will impose a strict lockdown in Ho Chi Minh City (HCMC) from 9 July for 15 days. Meanwhile, just two weeks before the Tokyo Olympics, Japan is set to declare its fourth state of emergency in Tokyo from 12 July to 20 August, raising the possibility of no spectators attending the games. Meanwhile, Singapore is the only country that has decided to ease its social restrictions from 12 July, as new cases remain low. Urgency on vaccination The recent outbreaks in the region has alerted the authorities that the key to exiting the pandemic is to accelerate vaccine procurement and roll-out.
    [Show full text]
  • Ситуация По Вакцинам От Covid-19 В Мире. Вопросы Коммуникации С Населением По Вакцинации От Covid-19
    Филиал «Научно-практический центр санитарно-эпидемиологической экспертизы и мониторинга» Ситуация по вакцинам от COVID-19 в мире. Вопросы коммуникации с населением по вакцинации от COVID-19 Алматы, 2021 г. Ситуация в мире по вакцинам против COVID-19 - Согласно данным Всемирной организации здравоохранения по состоянию на 19.01.2021 года в мире: - разрабатываются 237 вакцин-кандидатов: . из них проходят клинические стадии испытания - 64 вакцины . пре-клинические стадии проходят - 173 вакцин. используются 8 вакцин (Moderna, BioNTech / Pfizer, Oxford Biomedica и AstraZeneca, НИИ Гамалея (Спутник V), CanSino Biologics, Sinopharm (2), Sinovac / Instituto Butantan / Bio Farma). https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines Вакцины в мире Экстренно введенные В фазе 3 (20) В фазе 2 (21) В фазе 1 (43) вакцины • Moderna (США) • QazCovid in(Казахстан) • Medigen (Тайвань) • VIDO (Канада) • • • • Pfizer-BioNTech (Германия) SINOVAC (Китай) Arcturus (США) Genexine (Южная Корея) • Covaxin (Индия) • Спутник V (Gamaleya РФ) • Pfizer-BioNTech (Германия) • Walvax Biotechnology (Китай) • • • • AZD1222 (Британия-Франция) Clover Biopharmaceuticals (США) Gennova Biopharmaceuticals (Индия) ChulaCov19 (Китай) • West China Hospital of Sichuan • GeneOne Life Science (Южная Корея) • Covigenix VAX-001 (Канада) University (Китай) • Soberana 1 (Куба) • Symvivo (Канада) • mRNA-1273 (США) • COVAX (Франция) • CORVax12 (США) • CVnCoV (Германия) • SpyBiotech (Англия) • Vaxart (США) • AG0302-COVID19 (Япония) • Dynavax (США) • Merck (США)
    [Show full text]
  • En Este Número
    Boletín Científico No. 18 (1-10 julio/2021) EN ESTE NÚMERO VacCiencia es una publicación dirigida a Resumen de candidatos vacu- investigadores y especialistas dedicados a nales contra la COVID-19 ba- la vacunología y temas afines, con el ob- sadas en la plataforma de sub- jetivo de serle útil. Usted puede realizar unidad proteica en desarrollo a sugerencias sobre los contenidos y de es- nivel mundial. (segunda parte) ta forma crear una retroalimentación Artículos científicos más que nos permita acercarnos más a sus recientes de Medline sobre necesidades de información. vacunas. Patentes más recientes en Patentscope sobre vacunas. Patentes más recientes en USPTO sobre vacunas. 1| Copyright © 2020. Todos los derechos reservados | INSTITUTO FINLAY DE VACUNAS Resumen de vacunas contra la COVID-19 basadas en la plataforma de subunidad proteica en desarrollo a nivel mundial (segunda parte) Las vacunas de subunidades antigénicas son aquellas en las que solamente se utilizan los fragmentos específicos (llamados «subunidades antigénicas») del virus o la bacteria que es indispensable que el sistema inmunitario reconozca. Las subunidades antigénicas suelen ser proteínas o hidratos de carbono. La mayoría de las vacunas que figuran en los calendarios de vacunación infantil son de este tipo y protegen a las personas de enfermedades como la tos ferina, el tétanos, la difteria y la meningitis meningocócica. Este tipo de vacunas solo incluye las partes del microorganismo que mejor estimulan al sistema inmunitario. En el caso de las desarrolladas contra la COVID-19 contienen generalmente, la proteína S o fragmentos de la misma como el Dominio de Unión al Receptor (RBD, por sus siglas en inglés).
    [Show full text]